title: Efficacy and safety of rituximab as maintenance therapy for relapsing granulomatosis with polyangiitis—a case series.
abstract: The objective of this work was to study the efficacy and safety of pre-emptive rituximab (RTX) in a series of patients with severe relapsing granulomatosis with polyangiitis (GPA). GPA is a systemic vasculitis with a high relapse rate despite successful remission induction. Drug toxicity with repeated induction treatments and long-standing immunosuppression poses a problem. Based on the findings in reports on RTX for rheumatoid arthritis, we treated patients with severe relapsing GPA with pre-emptive RTX, 1,000 mg 2 weeks apart every 6 months, aiming at achieving sustainable remission. All patients at one centre with relapsing GPA in spite of traditional maintenance treatment, who had received more than or equal to three cycles of RTX as regularly repeated pre-emptive maintenance therapy every 6 months, were included in this retrospective study. Information on disease manifestations and activity, treatments, lab parameters and adverse events was extracted from the medical files. Of the 12 included patients, all with a positive proteinase 3–anti-neutrophil cytoplasmic antibodies, generalised disease and a median disease duration of 35 months (21–270), 92% (11/12) achieved sustainable remission during a median follow-up time of 32 months (range 21–111) from first RTX treatment. Concomitant immunosuppressants were reduced. Infections were the most common adverse events, but infections were an issue also before the start of RTX. RTX administered every 6 months seems to be an effective maintenance treatment in a population with severe, relapsing long-standing GPA. Granulomatous as well as vasculitic manifestations responded equally well. Infections are a problem in this patient group but no new safety problems were identified.
authors: A
authors: A
authors: Knight
authors: H
authors: H
authors: Hallenberg
authors: E
authors: E
authors: Baecklund
mesh_terms: D000293:Adolescent; D000328:Adult; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000276:immunology; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use; D005260:Female; D014890:Granulomatosis with Polyangiitis / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012074:Remission Induction; D012189:Retrospective Studies; D000069283:Rituximab; D056647:Systemic Vasculitis / Q000188:drug therapy; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D019268:Antibodies, Antineutrophil Cytoplasmic; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D000069283:Rituximab
references: J Rheumatol. 2010 Mar;37(3):558-67
references: 20110520
references: Clin J Am Soc Nephrol. 2010 Aug;5(8):1394-400
references: 20498238
references: Arthritis Rheum. 1994 Feb;37(2):187-92
references: 8129773
references: Ann Rheum Dis. 2009 Mar;68(3):310-7
references: 18413444
references: N Engl J Med. 2003 Jul 3;349(1):36-44
references: 12840090
references: Immunity. 2004 May;20(5):517-27
references: 15142521
references: N Engl J Med. 2012 Jul 19;367(3):214-23
references: 22808956
references: Arthritis Rheum. 2011 Aug;63(8):2209-14
references: 21560117
references: J Intern Med. 2005 Jun;257(6):540-8
references: 15910558
references: Arthritis Rheum. 2008 Sep;58(9):2908-18
references: 18759282
references: Arthritis Rheum. 2012 Nov;64(11):3770-8
references: 22730028
references: Autoimmun Rev. 2012 Jul;11(9):646-52
references: 22146313
references: N Engl J Med. 2010 Jul 15;363(3):221-32
references: 20647199
references: Arthritis Rheum. 2012 Nov;64(11):3760-9
references: 22729997
references: J Immunol. 1982 Jun;128(6):2453-7
references: 6978904
references: Arthritis Rheum. 1990 Aug;33(8):1101-7
references: 2202308
references: Blood. 2009 May 14;113(20):4834-40
references: 19264918
references: Arthritis Rheum. 2001 Apr;44(4):912-20
references: 11318006
references: Ann Rheum Dis. 2012 Mar;71(3):327-33
references: 22021864
references: Cleve Clin J Med. 2012 Nov;79 Suppl 3:S50-3
references: 23203647
references: Arthritis Rheum. 2009 Jul;60(7):2156-68
references: 19565480
references: N Engl J Med. 2010 Jul 15;363(3):211-20
references: 20647198
references: Rheumatology (Oxford). 2011 Dec;50(12):2223-32
references: 21926153
references: Ann Intern Med. 1992 Mar 15;116(6):488-98
references: 1739240
references: J Rheumatol. 2012 Jan;39(1):125-30
references: 22089465
references: Scand J Rheumatol. 2012 Mar;41(2):116-9
references: 22118245
references: Ann Rheum Dis. 2004 Oct;63(10):1307-11
references: 15130900
references: J Allergy Clin Immunol. 1999 May;103(5 Pt 1):885-94
references: 10329824
references: Ann Rheum Dis. 2007 May;66(5):605-17
references: 17170053